A new trading day began on Tuesday, with Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) stock price up 3.43% from the previous day of trading, before settling in for the closing price of $9.05. BCRX’s price has ranged from $4.03 to $9.11 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 203.39% over the last five years. Meanwhile, its annual earnings per share averaged 69.57%. With a float of $195.37 million, this company’s outstanding shares have now reached $207.12 million.
The firm has a total of 536 workers. Let’s measure their productivity. In terms of profitability, gross margin is 97.91%, operating margin of -9.84%, and the pretax margin is -30.09%.
Biocryst Pharmaceuticals Inc (BCRX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Biocryst Pharmaceuticals Inc is 5.68%, while institutional ownership is 79.18%. The most recent insider transaction that took place on Dec 13 ’24, was worth 52,780. In this transaction Director of this company sold 7,000 shares at a rate of $7.54, taking the stock ownership to the 86,638 shares. Before that another transaction happened on Dec 13 ’24, when Company’s Director proposed sale 7,000 for $7.51, making the entire transaction worth $52,584.
Biocryst Pharmaceuticals Inc (BCRX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 69.57% per share during the next fiscal year.
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) Trading Performance Indicators
Here are Biocryst Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.61, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach -0.09 in one year’s time.
Technical Analysis of Biocryst Pharmaceuticals Inc (BCRX)
Analysing the last 5-days average volume posted by the [Biocryst Pharmaceuticals Inc, BCRX], we can find that recorded value of 3.95 million was better than the volume posted last year of 2.74 million. As of the previous 9 days, the stock’s Stochastic %D was 95.09%. Additionally, its Average True Range was 0.38.
During the past 100 days, Biocryst Pharmaceuticals Inc’s (BCRX) raw stochastic average was set at 96.55%, which indicates a significant increase from 95.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 45.17% in the past 14 days, which was lower than the 51.93% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.89, while its 200-day Moving Average is $7.35. Now, the first resistance to watch is $9.51. This is followed by the second major resistance level at $9.66. The third major resistance level sits at $9.87. If the price goes on to break the first support level at $9.15, it is likely to go to the next support level at $8.94. Now, if the price goes above the second support level, the third support stands at $8.79.
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) Key Stats
With a market capitalization of 1.94 billion, the company has a total of 207,133K Shares Outstanding. Currently, annual sales are 331,410 K while annual income is -226,540 K. The company’s previous quarter sales were 117,090 K while its latest quarter income was -14,030 K.
